Mabel Mardones, MD
@mabelonc
Followers
478
Following
4K
Media
12
Statuses
1K
mom of 3 boys, breast medical oncologist, equity, @latinasinmed, @womeninmedicine, @theusonetwork @scri
Joined June 2016
🩺 How Aspirin Prevents Cancer Metastasis—Finally Explained For over 50 years, aspirin has been linked to reduced cancer metastasis—but why remained unclear. New mechanistic work now provides a clear immunologic explanation. 🔬 Key Discovery Yang et al. identify a
nejm.org
A new study shows that aspirin enhances antimetastatic immunity by decreasing platelet activation, thereby releasing T cells from suppression by thromboxane A2.
0
66
207
Great news for patients. Now we have to decide how to optimally use this combo! FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer! Maintenance and added value of P are key issues. @OncoAlert
targetedonc.com
FDA approves T-DXd plus pertuzumab for HER2-positive metastatic breast cancer, showing significant improvements in progression-free survival and response rates.
1
9
33
A great, practical guide.
Can we combine radiotherapy with CDK4/6i, HER2, PARP or mTOR targeted agents? Just out on the green journal the ESMO-ESTRO systematic review (107 studies) and Delphi consensus on the topic. Huge work, masterfully led by Evert van Aken. Read it here: https://t.co/K1lW02TiFL
0
1
1
Our meta-analysis and cost-effectiveness analysis show a low incidence of LVEF drop, esp w/ADCs. Routine echocardiograms every 3 months are not cost-effective for most patients with standard cardiovascular risk. Is it time to change practice? @stolaney1 @AnaBaracCardio #sabcs25
1
15
42
Amazing news for our patients! This sets a new standard for our first line HER2 positive mBC patient, the first since Cleopatra 2015
The @US_FDA approves T-DXd/pertuzumab for the first-line treatment of HER2+ metastatic breast cancer, based on the DESTINY-Breast09 trial. Data on the T-DXd monotherapy arm of the study pending and highly awaited. https://t.co/VKRtZgvx8j
0
0
0
🚨 #SABCS25 Highlight — New Treatment Algorithm for mTNBC from @stolaney1 @DFCI_BreastOnc One of the updates from SABCS25 is this proposed new therapeutic algorithm for metastatic triple-negative breast cancer (mTNBC) — integrating recent advances across antibody–drug
2
30
77
Important work that helps validate patient experience. We need better preventative and treatment strategies for treatment associated CI
Honored to publish our study: "Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women" in Jama Oncology! https://t.co/Rfx7v7DHAD
@SWOG @KalinskyKevin @lynnhenrymd @ExactSciences
0
0
1
Fantastic @IDEOlogyHealth social media poll event tonight with a fantastic group of friends. I know they helped me clarify my thoughts on a lot of complicated very new data and how to integrate it all into my clinical practice. #SABCS25
2
5
21
HR+ Metastatic Breast Cancer: Progress, Regulatory Approvals, and the Trials Ahead— @LalehAmiri-Kordestani & @AngieDemichele moderated this special @FDAOncology session, which featured Melanie Royce, Maria Garcia-Jimenez, Christy Osgood, & @StephWalkerMD. #SABCS25 @mariagjMD
0
5
12
50yo patient with de-novo ER+/HER2+ MBC with multiple liver metastases; normal liver function. What 1L would you choose, assuming all available?
2
14
42
“Most important trial in SABCS25” commented by Eric P. Winer. WISDOM trial: Risk-based breast cancer screening was non-inferior for safety, with no increase in stage ≥2B cancers, while reducing biopsies and mammograms. Cancer incidence was similar, but shifted toward earlier
0
6
17
So proud of our amazing leader Dr Sara Tolaney @stolaney1 from @DFCI_BreastOnc receiving the 2025 @AACR Outstanding Investigator Award; teaching us all important core lessons for success!
4
12
52
IDEO Xchange: SERENA-6: Switching to camizestrant + CDK4/6i atESR1m detection delayed QoL decline (23.0 vs 6.4 mo vs AI). How impactful are these PRO findings on your treatment decisions?
0
4
5
IDEO Xchange: TROPION-Breast02: Dato-DXd in 1L mTNBC showed strong efficacy (PFS, OS, response rates). How practice-changing are these results?
0
4
3
IDEO Xchange: Which trial shows greater clinical impact? 🔹 DESTINY-Breast11: T-DXd ± THP improved pCR vs ddAC-THP 🔹 DESTINY-Breast05: T-DXd cut IDFS risk by 53% vs T-DM1
0
7
5
IDEO Xchange: DESTINY-Breast05: T-DXd cut recurrence/death risk by 53% vs T-DM1 & raised 3-yr IDFS to 92.4% vs 83.7%. How practice-changing is this for high-risk HER2+ eBC?
0
6
3
IDEO Xchange: DESTINY-Breast11: T-DXd+THP achieved pCR 67.3% vs 56.3% with ddAC-THP (RCB 0/I: 81.3% vs 69.1%). If approved, how likely are you to adopt this regimen in practice?
0
9
5
Join us live on X tonight at 9:30 pm Central for our IDEO Xchange discussing the latest developments in #breastcancer with Drs. @Dr_RShatsky @hoperugo @AbiSivaMD @mabelonc @DrWGradishar @MeganKruseMD @gandhi_shipra @dougmarksmd @Neil_Iyengar @kristinrojasmd @NinaOncMD
0
5
6
The first new adjuvant endocrine treatment to improve outcomes for breast cancer in decades. Tucatinib improving outcomes in the first line HER2+ setting. First phase 3 data with SG in chemo-naive pts with HR+ MBC. And so much more. See you in a few days in San Antonio! #SABCS25
6
95
230